Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The therapeutic effects of 1 g/day cimetidine in short-term courses of 21 days have been tested by a double blind study in 20 patients, of which 17 with duodenal ulcer and 3 with both gastric and duodenal ulcerations, in comparison with a similar group of patients who received placebo. The symptomatology was characteristic in all the cases, X-ray presence of ulcer in 17 patients and indirect signs in 3, endoscopic examination positive. The total volume of ClH nocturnal secretion, as well as the basal and maximal hydrochloric secretions decreased, but the differences with respect to the initial values were not statistically significant; the inhibition of gastric acid secretion by cimetidine amounted to 40%; ulcer healing was noted in 3 out of 17 cases. The adverse effects were rare: sleeplessness in 6 cases, asthenia in 4, dry mouth in 3. The differences between the results of cimetidine administration and those in the placebo group had no statistical significance. It is concluded that a short-term course of 21 days is not sufficient to obtain healing of the gastric or duodenal ulcerations.
 ...
PMID:The value of cimetidine in the treatment of gastroduodenal ulcer. 388 43

Twenty-one healthy, caucasian, male volunteers completed this randomized single blind, multiple-dose, crossover bioavailability study during which either phentermine HCl capsules (Minobese Forte, reference product) or phentermine base capsules (Duromine, test product) were ingested once daily for 14 days. A washout period of 14 days was allowed between the two treatment phases. On profile days (day 14 of each treatment phase) subjects remained recumbent for 24 hours after drug administration. Serial venous blood samples were drawn over the 24 hour dosing interval for plasma phentermine assay by gas chromatography. The 90% confidence intervals for the "test/reference" mean ratios of the pharmacokinetic variables Cmax,norm, Cmin,norm, AUCnorm (normalized for difference in the dose of phentermine base), %PTF and T75% Cmax, all fell within the bioequivalence range of 80% to 125%. With the aid of trough plasma phentermine concentrations, it was established that steady-state was reached after 14 days of once daily administration of either product. Adverse events experienced on both treatments included prolonged or recurrent episodes of insomnia, nausea, headache, dry mouth and dizziness. No clinically relevant changes in clinical chemistry or hematology variables occurred during the study.
 ...
PMID:Steady-state pharmacokinetics of phentermine extended-release capsules. 822 80

The phentermine, an appetite suppressant, has been widely applied in Korea since 2004. However, there have been relatively few reports about the efficacy and the safety of phentermine in Korea. The aim of this study is to verify the effect of phentermine on weight reduction and the safety in Korean patients. This randomized, double-blind, placebo- controlled study had been performed between February and July, 2005, in Seoul on 68 relatively healthy obese adults whose body mass index was 25 kg/m2 or greater. They received phentermine-HCl 37.5 mg or placebo once daily with behavioral therapy for obesity. The primary endpoints were the changes of body weight and waist circumference from the baseline in the intention-to-treat population. Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group (weight: -6.7 +/- 2.5 kg, p < 0.001; waist circumference: -6.2 +/- 3.5 cm, p < 0.001). Significant number of subjects in phentermine group accomplished weight reduction of 5% or greater from the baseline and 10% or more (p < 0.001). There were no significant differences in systolic and diastolic blood pressure between the groups (p = 0.122 for systolic BP; p = 0.219 for diastolic BP). Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group. Most side effects of phentermine were mild to moderate in intensity. Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obese people.
 ...
PMID:Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. 1706 5